Retatrutide Phase 2: Type 2 Diabetes Trial Data

Retatrutide phase 2 type 2 diabetes weight loss percentage data come from a randomised, double-blind, placebo-controlled trial published in The Lancet in 2023. Retatrutide is an investigational triple receptor agonist acting on GLP-1, GIP, and glucagon receptors, currently under study in the Phase 3 TRANSCEND and TRIUMPH programmes. It holds no marketing authorisation in the UK or elsewhere and is accessible only within an authorised clinical trial. This article summarises what the Phase 2 findings reported, the safety signals observed, and the current regulatory position for anyone seeking factual, evidence-based information.

What is retatrutide and why is it being studied?

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, studied for obesity and type 2 diabetes. It has no UK marketing authorisation and is accessible only within authorised clinical trials.

Retatrutide is an investigational medicine being studied as a potential treatment for obesity and type 2 diabetes, but it holds no marketing authorisation in the UK or anywhere else and can only be accessed within an authorised clinical trial. It is a triple receptor agonist, meaning it acts simultaneously on three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism distinguishes it pharmacologically from currently licensed dual agonists and single agonists, though no head-to-head trials have compared it directly with any licensed treatment.

The rationale for studying a triple agonist lies in the complementary roles of these three pathways. GLP-1 and GIP receptor activation supports insulin secretion and appetite regulation, while glucagon receptor agonism is thought to increase energy expenditure and promote fat breakdown.^[15][1] Researchers hypothesise that engaging all three pathways simultaneously may produce greater metabolic effects than targeting fewer receptors, though this remains under investigation.

The Phase 3 programme, known as TRIUMPH (for obesity) and TRANSCEND (for type 2 diabetes), is generating longer-term safety and efficacy data.^[12][13] Initial Phase 3 results have begun to be reported, including topline and conference data from TRIUMPH and early readouts from the TRANSCEND-T2D-1 study, though full peer-reviewed publications are not yet available for all arms of the programme. Until the complete dataset has been reviewed by regulators, retatrutide remains experimental. Anyone interested in licensed weight-management treatments should speak with their GP.

What did the Phase 2 trial find in people with type 2 diabetes?

The Phase 2 Lancet trial (2023) found reductions in both body weight and HbA1c across multiple retatrutide dose groups versus placebo over 36 weeks in people with type 2 diabetes on metformin.

The Phase 2 trial of retatrutide in people with type 2 diabetes, published in The Lancet in 2023, found reductions in both body weight and glycated haemoglobin (HbA1c) across multiple dose groups compared with placebo over a 36-week treatment period.^[1] This was a randomised, double-blind, placebo-controlled trial conducted across multiple sites, and its findings should be understood in the context of a relatively small Phase 2 population and a duration that does not capture long-term outcomes.

Participants had established type 2 diabetes and were receiving background treatment with metformin, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.^[1] The trial assessed several dose levels of retatrutide administered as a once-weekly subcutaneous injection. Across the active treatment arms, reductions in HbA1c were observed alongside the weight reductions, suggesting a dual metabolic effect. Phase 2 trials are designed primarily to assess safety, tolerability and dose-ranging rather than to confirm efficacy at a population level.

The TRANSCEND-T2D-1 Phase 3 study has since reported initial results, extending the evidence base beyond the Phase 2 findings, though full peer-reviewed publication of all Phase 3 data is pending. These Phase 2 findings, while informative, cannot alone be used to draw firm conclusions about how retatrutide would perform in broader clinical practice.

How do the weight loss percentages compare across trial groups?

At the highest dose (12 mg), participants achieved a mean body weight reduction of approximately 16.9% from baseline at 36 weeks, with lower doses showing progressively smaller reductions.

In the Phase 2 Lancet trial (2023), participants with type 2 diabetes receiving the highest dose of retatrutide (12 mg, escalated over the treatment period) achieved a mean body weight reduction of approximately 16.9% from baseline at 36 weeks, compared with a modest reduction in the placebo group. Lower dose groups showed progressively smaller reductions, demonstrating a clear dose-response relationship within the trial. These figures are trial findings in a specific, selected population over a defined period and do not represent what any individual would experience.

Several limitations are important when interpreting these percentages. The trial excluded people who were pregnant, breastfeeding, or planning pregnancy, and required participants to use effective contraception throughout. The 36-week duration means longer-term weight trajectory, including whether weight loss is maintained or regresses, is not captured in this dataset. Participants had type 2 diabetes managed with specific background therapies, so the results may not generalise to people with different clinical profiles.

Initial Phase 3 results from the TRIUMPH obesity programme have been presented at conference level, and the TRANSCEND-T2D-1 Phase 3 study has reported topline data, though full peer-reviewed publications are pending for several arms. These larger, longer studies will provide more reliable estimates of weight outcomes across broader populations. No comparison with licensed medicines such as semaglutide or tirzepatide can be drawn from these figures, as no head-to-head trials have been conducted.

What side effects and safety signals did the Phase 2 data show?

The most common side effects were gastrointestinal; increases in heart rate were also observed across active groups, a known effect of glucagon receptor agonism requiring further Phase 3 evaluation.

The most commonly reported side effects in the Phase 2 retatrutide trial were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation, a pattern consistent with other medicines acting on GLP-1 receptors. These effects were generally more frequent at higher doses and tended to occur during dose escalation, with many participants experiencing improvement over time. Injection-site reactions were also reported.

Increases in heart rate were observed across active treatment groups in the Phase 2 trial. This is a recognised pharmacological effect associated with glucagon receptor agonism and is being evaluated further in the Phase 3 programme.

As with other medicines in this class, nausea and vomiting carry a risk of dehydration, and participants were advised to maintain adequate fluid intake. The UK SmPCs for licensed GLP-1 receptor agonists note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome; this will be an area of ongoing surveillance for retatrutide as the evidence base develops.^[4][5] Gallbladder and biliary events are also a recognised class consideration for incretin-based therapies and will require monitoring in the Phase 3 programme.^[9][10]

People with pre-existing diabetic retinopathy should be aware that rapid improvement in HbA1c has been associated with early worsening of diabetic retinopathy in some individuals, a phenomenon documented in the DCCT and referenced in NICE guidance on diabetic retinopathy (NG242).^[8][7] This is a class consideration relevant to any treatment that produces rapid glycaemic improvement, and anyone with established retinopathy should ensure they maintain their diabetic eye screening appointments and discuss this risk with their trial team before and during treatment.

Because retatrutide is not authorised, it does not yet have a UK Summary of Product Characteristics. Safety data continue to accumulate through the clinical trial programme. Anyone participating in a retatrutide trial who experiences a suspected adverse event should report it to the trial team under the study protocol, and should inform any emergency clinician that they are enrolled in a clinical trial. Suspected side effects of medicines can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you experience severe abdominal pain, persistent vomiting or signs of a serious allergic reaction, contact your GP or call NHS 111 for urgent advice; call 999 only in a life-threatening emergency.

What is retatrutide's current regulatory status in the UK?

Retatrutide has no UK marketing authorisation; the MHRA has not authorised it and NICE has issued no guidance, so it remains available only within authorised clinical trials.

Retatrutide has no marketing authorisation in the UK and cannot be prescribed or supplied outside an authorised clinical trial. The MHRA has not authorised retatrutide, and NICE has not issued any guidance on it. No timeline for a UK marketing authorisation application can be given, and no date for potential availability should be assumed. The Phase 3 TRIUMPH and TRANSCEND programmes are generating the long-term safety and efficacy data that any regulatory submission would require, but the outcome and timing of any future application remain uncertain.

Because retatrutide is unlicensed, any product sold online or through informal channels and described as retatrutide is not a licensed medicine and may be falsified, counterfeit or of unknown composition. Purchasing such products carries serious health risks. People who are interested in licensed treatments for weight management or type 2 diabetes should speak with their GP, who can discuss options that are currently authorised by the MHRA and, where applicable, recommended by NICE for NHS use. Commissioning decisions for licensed weight-management medicines are made by local Integrated Care Boards (ICBs), and eligibility criteria vary by area.^[16]

For people with type 2 diabetes, several licensed treatments are available, including medicines authorised both for glycaemic management and for chronic weight management. The regulatory landscape may change as Phase 3 data are published and reviewed, but until the MHRA grants a marketing authorisation, retatrutide remains an investigational medicine available only within the controlled setting of an authorised clinical trial.

Frequently Asked Questions